Literature DB >> 29240609

Effects of Propofol on Cellular Bioenergetics in Human Skeletal Muscle Cells.

Adéla Krajčová1,2,3, Nils Gunnar Løvsletten4, Petr Waldauf1, Vladimír Frič5, Moustafa Elkalaf2,3, Tomáš Urban1, Michal Anděl2, Jan Trnka2,3, G Hege Thoresen4, František Duška1.   

Abstract

OBJECTIVES: Propofol may adversely affect the function of mitochondria and the clinical features of propofol infusion syndrome suggest that this may be linked to propofol-related bioenergetic failure. We aimed to assess the effect of therapeutic propofol concentrations on energy metabolism in human skeletal muscle cells.
DESIGN: In vitro study on human skeletal muscle cells. SETTINGS: University research laboratories.
SUBJECTS: Patients undergoing hip surgery and healthy volunteers.
INTERVENTIONS: Vastus lateralis biopsies were processed to obtain cultured myotubes, which were exposed to a range of 1-10 μg/mL propofol for 96 hours.
MEASUREMENTS AND MAIN RESULTS: Extracellular flux analysis was used to measure global mitochondrial functional indices, glycolysis, fatty acid oxidation, and the functional capacities of individual complexes of electron transfer chain. In addition, we used [1-C]palmitate to measure fatty acid oxidation and spectrophotometry to assess activities of individual electron transfer chain complexes II-IV. Although cell survival and basal oxygen consumption rate were only affected by 10 μg/mL of propofol, concentrations as low as 1 μg/mL reduced spare electron transfer chain capacity. Uncoupling effects of propofol were mild, and not dependent on concentration. There was no inhibition of any respiratory complexes with low dose propofol, but we found a profound inhibition of fatty acid oxidation. Addition of extra fatty acids into the media counteracted the propofol effects on electron transfer chain, suggesting inhibition of fatty acid oxidation as the causative mechanism of reduced spare electron transfer chain capacity. Whether these metabolic in vitro changes are observable in other organs and at the whole-body level remains to be investigated.
CONCLUSIONS: Concentrations of propofol seen in plasma of sedated patients in ICU cause a significant inhibition of fatty acid oxidation in human skeletal muscle cells and reduce spare capacity of electron transfer chain in mitochondria.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29240609     DOI: 10.1097/CCM.0000000000002875

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  5 in total

1.  Propofol infusion-like syndrome in a dog.

Authors:  John M Mallard; Teresa M Rieser; Nathan W Peterson
Journal:  Can Vet J       Date:  2018-11       Impact factor: 1.008

2.  Single dose of propofol causing propofol infusion syndrome in a newborn.

Authors:  C Michel-Macías; D A Morales-Barquet; A M Reyes-Palomino; J A Machuca-Vaca; A Orozco-Guillén
Journal:  Oxf Med Case Reports       Date:  2018-06-18

3.  Major elective abdominal surgery acutely impairs lower limb muscle pyruvate dehydrogenase complex activity and mitochondrial function.

Authors:  Ryan Atkins; Dumitru Constantin-Teodosiu; Krishna K Varadhan; Despina Constantin; Dileep N Lobo; Paul L Greenhaff
Journal:  Clin Nutr       Date:  2020-07-14       Impact factor: 7.324

4.  The effect of adenosine triphosphate on propofol-induced myopathy in rats: a biochemical and histopathological evaluation.

Authors:  Kezban Tuna Ozkaloglu Erdem; Zehra Bedir; Irem Ates; Ufuk Kuyrukluyildiz; Taha Abdulkadir Coban; Gulce Naz Yazici; Yusuf Kemal Arslan; Zeynep Suleyman; Halis Suleyman
Journal:  Korean J Physiol Pharmacol       Date:  2021-01-01       Impact factor: 2.016

5.  Kinetic characteristics of propofol-induced inhibition of electron-transfer chain and fatty acid oxidation in human and rodent skeletal and cardiac muscles.

Authors:  Tomáš Urban; Petr Waldauf; Adéla Krajčová; Kateřina Jiroutková; Milada Halačová; Valér Džupa; Libor Janoušek; Eva Pokorná; František Duška
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.